Galderma launches RESTYLANE® EYELIGHT™, a targeted hyaluronic acid filler to reduce under-eye shadows
– Developed with NASHA™ gel technology which precise placement to fill under-eye hollows ,
– The NASHA gel technology gives patients predictable outcomes and provides natural-looking results, helping them to look less tired and more rested1,
RESTYLANE EYELIGHT is trusted to deliver high patient satisfaction, with clinical results which demonstrating that 6.5 months after the first treatment, 88.6% of people reported looking less tired and 91.4% of people still felt attractive due to the improvement in their dark circles.1 In addition, 94.3% of people who tried RESTYLANE EYELIGHT would recommend it and repeat treatment.1 In Europe, research has indicated that 66% of people are bothered by their under-eye circles.
RESTYLANE EYELIGHT contains hyaluronic acid which is part of Galderma’s proprietary NASHA gel technology. This is combined with lidocaine, a local anaesthetic, to allow for a more comfortable treatment.
As a trusted and premium brand for 25 years, Restylane has a proven track record in delivering effective treatment. Over the decades, 50 million RESTYLANE treatments have been administered across the globe.7
Data on file – (MA-48305).
Data on file – data submitted for publication (Consensus).
Verpaele A, Strand A. Restylane SubQ, a non-animal stabilized hyaluronic acid gel for soft tissue augmentation of the mid- and lower face. Aesthetic Surgery Journal. 2006 Jan;26(1):S10–7.
Stutman RL, Codner MA. Tear Trough Deformity: Review of Anatomy and Treatment Options. Aesthetic Surgery Journal. 2012 May 1;32(4):426–40.
Data on file (MA-46075). European market survey by Opticom and Galderma Q4, 2020
Data on File – (MA39680) Restylane 50 million treatments
Data on file (MA-47865). Summary of Restylane Publications Analysis